Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses

Keisuke Sunakawa, Ichiro Tsukimoto, Yoshikiyo Toyonaga, Yukiko Tsunematsu, Naoichi Iwai, Yusuke Tanigawara

Research output: Contribution to journalArticle

Abstract

We studied the efficacy, safety and pharmacokinetics of micafungin(MCFG) pediatric patients with deep mycoses, and conducted a multicenter, non-blinded, uncontrolled study to estimate the pediatric dosage and administration schedule. The results in the 20 cases that were enrolled in this study are as follows: 1. In terms of the overall clinical effect, the study drug was "effective" in 10/14 cases (71.4%) overall, 7/11 cases (63.6%) of candidiasis, and all of the 3 cases of aspergillosis. 2. The percent incidence of adverse drug reactions (accompanying symptoms) was 5% (1/20 cases), and an anaphylactoid reaction occurred in 1 case only. The percent incidence of adverse drug reactions (abnormal laboratory test value changes) was 25.0% (5/20 cases), and the most frequently seen events were liver function disorders, such as increased AST, increased ALT, increased ALP, increased γ-GTP, etc. None of these events were serious, and it was not necessary to discontinue or decrease the dose of the study drug in any of the patients. The adverse drug reactions were not dose-dependent either. 3. Both Cmax and Cmin showed linearity in the dose range of 1.0 to 6.0 mg/kg/day based on the results of the pharmacokinetics study. The half-life was approximately 13 hours and was generally constant, irrespective of the dose level and age. Based on the abovementioned results, the efficacy, safety and in vivo pharmacokinetics of micafungin in pediatric patients, including school children, infants, and nursing infants, at doses (1.0 to 6.0 mg/kg/day) calculated with body weight adjustment from the approved adult dosage (50 to 300 mg/day), did not differ widely from those in adult patients, and the drug is expected to become a useful drug for pediatric patients with deep mycoses.

Original languageEnglish
Pages (from-to)190-201
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume56
Issue number2
Publication statusPublished - 2008 Mar

Fingerprint

Mycoses
Pharmacokinetics
Pediatrics
Safety
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Aspergillosis
Candidiasis
Incidence
Guanosine Triphosphate
Half-Life
Appointments and Schedules
Nursing
Body Weight
micafungin
Liver

Keywords

  • Clinical trial
  • Fungal infection
  • Micafungin
  • Pediatric patient

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sunakawa, K., Tsukimoto, I., Toyonaga, Y., Tsunematsu, Y., Iwai, N., & Tanigawara, Y. (2008). Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses. Japanese Journal of Chemotherapy, 56(2), 190-201.

Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses. / Sunakawa, Keisuke; Tsukimoto, Ichiro; Toyonaga, Yoshikiyo; Tsunematsu, Yukiko; Iwai, Naoichi; Tanigawara, Yusuke.

In: Japanese Journal of Chemotherapy, Vol. 56, No. 2, 03.2008, p. 190-201.

Research output: Contribution to journalArticle

Sunakawa, K, Tsukimoto, I, Toyonaga, Y, Tsunematsu, Y, Iwai, N & Tanigawara, Y 2008, 'Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses', Japanese Journal of Chemotherapy, vol. 56, no. 2, pp. 190-201.
Sunakawa, Keisuke ; Tsukimoto, Ichiro ; Toyonaga, Yoshikiyo ; Tsunematsu, Yukiko ; Iwai, Naoichi ; Tanigawara, Yusuke. / Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses. In: Japanese Journal of Chemotherapy. 2008 ; Vol. 56, No. 2. pp. 190-201.
@article{2e6f041e231a4f7a990023cfbafbff9f,
title = "Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses",
abstract = "We studied the efficacy, safety and pharmacokinetics of micafungin(MCFG) pediatric patients with deep mycoses, and conducted a multicenter, non-blinded, uncontrolled study to estimate the pediatric dosage and administration schedule. The results in the 20 cases that were enrolled in this study are as follows: 1. In terms of the overall clinical effect, the study drug was {"}effective{"} in 10/14 cases (71.4{\%}) overall, 7/11 cases (63.6{\%}) of candidiasis, and all of the 3 cases of aspergillosis. 2. The percent incidence of adverse drug reactions (accompanying symptoms) was 5{\%} (1/20 cases), and an anaphylactoid reaction occurred in 1 case only. The percent incidence of adverse drug reactions (abnormal laboratory test value changes) was 25.0{\%} (5/20 cases), and the most frequently seen events were liver function disorders, such as increased AST, increased ALT, increased ALP, increased γ-GTP, etc. None of these events were serious, and it was not necessary to discontinue or decrease the dose of the study drug in any of the patients. The adverse drug reactions were not dose-dependent either. 3. Both Cmax and Cmin showed linearity in the dose range of 1.0 to 6.0 mg/kg/day based on the results of the pharmacokinetics study. The half-life was approximately 13 hours and was generally constant, irrespective of the dose level and age. Based on the abovementioned results, the efficacy, safety and in vivo pharmacokinetics of micafungin in pediatric patients, including school children, infants, and nursing infants, at doses (1.0 to 6.0 mg/kg/day) calculated with body weight adjustment from the approved adult dosage (50 to 300 mg/day), did not differ widely from those in adult patients, and the drug is expected to become a useful drug for pediatric patients with deep mycoses.",
keywords = "Clinical trial, Fungal infection, Micafungin, Pediatric patient",
author = "Keisuke Sunakawa and Ichiro Tsukimoto and Yoshikiyo Toyonaga and Yukiko Tsunematsu and Naoichi Iwai and Yusuke Tanigawara",
year = "2008",
month = "3",
language = "English",
volume = "56",
pages = "190--201",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses

AU - Sunakawa, Keisuke

AU - Tsukimoto, Ichiro

AU - Toyonaga, Yoshikiyo

AU - Tsunematsu, Yukiko

AU - Iwai, Naoichi

AU - Tanigawara, Yusuke

PY - 2008/3

Y1 - 2008/3

N2 - We studied the efficacy, safety and pharmacokinetics of micafungin(MCFG) pediatric patients with deep mycoses, and conducted a multicenter, non-blinded, uncontrolled study to estimate the pediatric dosage and administration schedule. The results in the 20 cases that were enrolled in this study are as follows: 1. In terms of the overall clinical effect, the study drug was "effective" in 10/14 cases (71.4%) overall, 7/11 cases (63.6%) of candidiasis, and all of the 3 cases of aspergillosis. 2. The percent incidence of adverse drug reactions (accompanying symptoms) was 5% (1/20 cases), and an anaphylactoid reaction occurred in 1 case only. The percent incidence of adverse drug reactions (abnormal laboratory test value changes) was 25.0% (5/20 cases), and the most frequently seen events were liver function disorders, such as increased AST, increased ALT, increased ALP, increased γ-GTP, etc. None of these events were serious, and it was not necessary to discontinue or decrease the dose of the study drug in any of the patients. The adverse drug reactions were not dose-dependent either. 3. Both Cmax and Cmin showed linearity in the dose range of 1.0 to 6.0 mg/kg/day based on the results of the pharmacokinetics study. The half-life was approximately 13 hours and was generally constant, irrespective of the dose level and age. Based on the abovementioned results, the efficacy, safety and in vivo pharmacokinetics of micafungin in pediatric patients, including school children, infants, and nursing infants, at doses (1.0 to 6.0 mg/kg/day) calculated with body weight adjustment from the approved adult dosage (50 to 300 mg/day), did not differ widely from those in adult patients, and the drug is expected to become a useful drug for pediatric patients with deep mycoses.

AB - We studied the efficacy, safety and pharmacokinetics of micafungin(MCFG) pediatric patients with deep mycoses, and conducted a multicenter, non-blinded, uncontrolled study to estimate the pediatric dosage and administration schedule. The results in the 20 cases that were enrolled in this study are as follows: 1. In terms of the overall clinical effect, the study drug was "effective" in 10/14 cases (71.4%) overall, 7/11 cases (63.6%) of candidiasis, and all of the 3 cases of aspergillosis. 2. The percent incidence of adverse drug reactions (accompanying symptoms) was 5% (1/20 cases), and an anaphylactoid reaction occurred in 1 case only. The percent incidence of adverse drug reactions (abnormal laboratory test value changes) was 25.0% (5/20 cases), and the most frequently seen events were liver function disorders, such as increased AST, increased ALT, increased ALP, increased γ-GTP, etc. None of these events were serious, and it was not necessary to discontinue or decrease the dose of the study drug in any of the patients. The adverse drug reactions were not dose-dependent either. 3. Both Cmax and Cmin showed linearity in the dose range of 1.0 to 6.0 mg/kg/day based on the results of the pharmacokinetics study. The half-life was approximately 13 hours and was generally constant, irrespective of the dose level and age. Based on the abovementioned results, the efficacy, safety and in vivo pharmacokinetics of micafungin in pediatric patients, including school children, infants, and nursing infants, at doses (1.0 to 6.0 mg/kg/day) calculated with body weight adjustment from the approved adult dosage (50 to 300 mg/day), did not differ widely from those in adult patients, and the drug is expected to become a useful drug for pediatric patients with deep mycoses.

KW - Clinical trial

KW - Fungal infection

KW - Micafungin

KW - Pediatric patient

UR - http://www.scopus.com/inward/record.url?scp=42049115635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049115635&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 190

EP - 201

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 2

ER -